GSK has continued its drive to bulk up its pipeline, taking global rights to a T-cell engager (TCE) for multiple myeloma, ...

The organisation should not automatically double simply because revenue does. These are directional ranges, not rules, but they expose an important principle: headcount growth should normally lag ...

The planned IPO comes after Electra raised $183 million in a Series C that completed last October, as it started dosing ...

RNA-targeted small molecules are rapidly emerging as one of the most exciting areas in drug discovery, with growing clinical validation demonstrating the potential to address historically undruggable ...

Khougazian – who is currently at investment group Flagship Pioneering – will take over as CEO of Chiesi on 15th October, ...

BioNTech and partner OncoC4's anti-CTLA-4 immunotherapy gotistobart almost doubled survival in a trial involving patients with a hard-to-treat form of lung cancer, ahead of a pivotal readout due next ...

AI company Anthropic has launched a new large language model (LLM) – Claude Fable 5 – claiming its capabilities as a tool for drug discovery and scientific research gives it a big lead over other ...

The Danish Group stated that the new corporate culture – dubbed 'The Novo Way' – centres around four Cs; namely, customer ...

The offer is legally conditioned upon the private equity company's Respighi BidCo vehicle securing at least a two-thirds ...

Etcamah is already approved in the US, Europe, and other markets for use in combination with a CDK4/6 inhibitor as a ...

GSK reported good clinical trial results with two of its lung cancer therapies – Jideytro and risvutatug rezetecan (ris-rez) ...

UK-headquartered Beacon Therapeutics has raised a whopping $170 million in second-round financing that will be used to advance a gene therapy for an inherited cause of blindness through a pivotal ...